More recently, immunotherapies with checkpoint blockade Abs directed against PD-1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have revolutionized the treatment of patients with metastatic cancer including melanoma (139) (Figure 5). Here, CTLA4 is linked to metastatic malignant neoplasm.